ARA-290
Also known as Cibinetide
Innate repair receptor agonist (EPO-derived 11-mer)
A non-erythropoietic erythropoietin fragment studied for small-fiber neuropathy and tissue repair.
How it works
Binds the innate repair receptor, the EPO receptor plus beta common receptor complex, activating anti-apoptotic and anti-inflammatory signaling without stimulating red cell production.
What research has shown
Sarcoidosis neuropathy trials report improved corneal nerve fiber measures and reduced neuropathic pain scores over 28 days.
Reported ranges in the literature
Low end
1 mg daily
Optimal
4 mg daily, the main trial dose
High end
8 mg daily in dose-ranging work
Frequency reported in the literature: Daily during study blocks
Protocol duration and pairing
Typical study duration
4 to 28 weeks in neuropathy and sarcoidosis studies.
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.